Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Thenoyltrifluoroacetone (TTFA) is a small molecule chelating agent and experimental pharmacological inhibitor of cellular respiration. Its primary mechanism is inhibition of mitochondrial respiratory chain complex II (succinate dehydrogenase), where it binds at the quinone reduction site and prevents ubiquinone from binding. This action blocks electron transport at complex II in animals and bacteria. TTFA also inhibits NADH fumarate reductase in bacteria and photosystem II in plants. It has been used as a reagent for spectrophotometric determination of metal ions due to its strong chelation properties with various metals including lanthanum, zirconium, hafnium and neodymium. In research settings it is used for organic synthesis (as a ligand), coordination chemistry (preparation of metal complexes), analytical chemistry (metal ion quantification), material science applications and as a fluorescent probe for detecting metals[1][2][3][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thenoyltrifluoroacetone.